Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences deferred tax assets (DTA), gross before valuation allowance ($M) ($M)
Form 10-K Note 15 Income Taxes
Latest, FY2025
6,052
Period ended Dec 31, 2025
Change on a year earlier
-16.0%
7,207 in FY2024
History
12 years
Since FY2014
Sources
10
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Deferred tax assets (DTA), gross before valuation allowance ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6,052 | -16.0% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 7,207 | +16.1% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 6,210 | +17.4% | Form 10-K (filed 2025-02-28) ↗ |
| FY2022 | Dec 31, 2022 | 5,289 | +14.0% | Form 10-K (filed 2024-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 4,641 | +6.5% | Form 10-K (filed 2023-02-22) ↗ |
| FY2020 | Dec 31, 2020 | 4,358 | +29.9% | Form 10-K (filed 2022-02-23) ↗ |
| FY2019 | Dec 31, 2019 | 3,355 | +117.9% | Form 10-K (filed 2021-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 1,540 | +18.4% | Form 10-K (filed 2019-02-26) ↗ |
| FY2017 | Dec 31, 2017 | 1,301 | -14.2% | Form 10-K (filed 2019-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 1,516 | +3.3% | Form 10-K (filed 2018-02-27) ↗ |
| FY2015 | Dec 31, 2015 | 1,468 | +36.9% | Form 10-K (filed 2017-02-27) ↗ |
| FY2014 | Dec 31, 2014 | 1,072 | – | Form 10-K (filed 2016-02-24) ↗ |
Breakdown
What makes up deferred tax assets (dta), gross before valuation allowance ($m)
- Deferred tax assets — Valuation allowance ($M)676 · FY2025
- Deferred tax assets, net of valuation allowance ($M)5,376 · FY2025
- DTA — Capitalized research & development and IPR&D ($M)1,773 · FY2025
- DTA — Net operating loss and capital loss carryforwards ($M)266 · FY2025
- DTA — R&D and foreign tax credit carryforwards ($M)353 · FY2025
- DTA — Accrued reserves and liabilities ($M)688 · FY2025
- DTA — Stock-based compensation ($M)83 · FY2025
- Deferred tax liabilities (DTL), total ($M)3,814 · FY2025
- DTL — Intangible assets ($M)3,209 · FY2025
- DTL — Property, plant and equipment ($M)288 · FY2025
Cite this data
StockData. (2026). Gilead Sciences Deferred tax assets (DTA), gross before valuation allowance ($M) ($M), annual FY2014–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/dta_gross_tot
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.